Transfusion of one unit or more of Rh-positive red blood cells normally causes circulating anti-D antibody to a.,!>pear 2-6 months later in 80-95% of Rh-persons. We asked whether transplant immunosuppression with cyc1osporine and corticostel'oids affects Rh immunization. Nin?t~n Rh-Ii.ver, heart, and heart-lung transplant recipients receIved 3-153 (median: 10) units 'Of Rh+ RBCs at surgery and were tested for anti-D >2 months later. Three patients developed anti-D at 11-15 days; one may have had an unusually rapid primary immune response and two were-secondary to previous exposure by pregnancy. None of the other 16 patients bad anti-D when tested 2.5-51 months later (13 patients, > 11.6 months). This low rate of Rhesus immunization in association with cyclosporine immunosuppression allows greater flexibility in meeting the transfusion needs ofRh-liver and heart transplant patients. Caution is stilI advised in young females and in patients who may ha~e been previously exposed to Rh+ RBCs by transfusJOn or by pregnancy prior to the availability of perinatal.Rh immune globulin twenty years ~go. Other humoral Immune responses_to some vaccines or infectious agents may also be impaired in transplant patients.
The D antigen on red blood cells is highly immunogenic. As little as 30 "I of RBCs has caused Rh immunization, and after a single I-m.l injection of Rh-+ RBCs, 10-40% of Rh-subjects develop antI-D (1) . After transfusions of one or more Rh+ units, anti-D appears 2-6 months later in 80-95% of Rhpersons (2) (3) (4) , Hemolytic disease of the newborn (HDN)' or hemolysis of Rh-incompatible RBC transfusions may then ensue.
Transplantation of livers, hearts, and heart-lungs can require large amounts of blood (5, 6). Because only 15% of white and 7% of black patien~s are Rh-, sufficient Rh-blood may not always be available for Rh-patients. In yiew of the setting of transplant immunosuppression, we studied our Rh-organ transplant recipients who received Rh· RBCs during surgery to determine whether they subsequently formed anti-D at th~ normal high rate. ThE' -results are of interest with regard to both transplant transfusion management and the pathogenesis of Rhesus immunization.
MATERIALS AND METHODS
Standard serologic methods (7) were employed in Central Blood Bank's transfusion service at the University of Pittsburgh, whichsupports adult organ transplants at Presbyterian-University Hospital and pediatric transplants at Children's Hospital of Pittsburgh. Bloodbank records were reviewed for Rh-Jjver, heart, and heart-lung transplant patients from 1981 to early 1987, and all who received Rh + RBCs Ouring surgery were assessed in retrospect for evidence of subsequent anti-D. None ofthese patients had anti-D at our center prior to surgery. We then BOught new samples from survivors for RBC antibody testing, including use of ficin·treated screening RBCs to enhance reactivity of Rh antibodies. We also reviewed,a second group of patients with anti-D prior to surgery in order to assess thp subspquent persistence of antibody. As is customary, we tested blood donors, but not patients, for the weak Rh+ DU phenotype present in 0.23--0.56% of all people (I), or about 1.5-3% of apparently Rh-patients.
For immunosuppression, our transplant programs have e1npl~yed cyclosporine, corticosteroids, adjunetive rabbit antiTymphocyte globulin, and-in recent years-OKT3 monoclonal antibody (8) (9) (10) (11) (12) .
RESULTS
The proportions of Rh-transplant patients recei\'ing intraoperative Rh~ RBCs because of rapid need and/or low Rhinventory were as follows: liver, 19 of 109; heart, 8 of 51; and heart-lung, 2 of 8. None received Rh immune globulin (RhIG).
Eight of the 29 patients given RhO< RBCs died within 2 months; three of these 8 had no anti-D by 7 weeks. Two other patients were not tested for RBC antibodies bevond one monthafter surgery. Thus, a total of 19 patients had ~ufficient follow· up for analysis.
Three liver transplant patients developed anti-D 11-15 days after receiving Rh+ RBCs. Two were women 64 and 53 years old, each with 3 past pregnancies and thus presumablv imm\!-nized prior to the licensure of perinatal RhlG in the U.S.A. in 1968. One received 29 Rh'; units during two liver transplants over 12 days. Three days later, anti-D was present in the serum and on circulating RBCs; concurrently, the hematocrit dropped from 34% to 26%, and the total and indirect bilirubin levels rose from 8.1 and 3. -total and inilirect bilirubin from 8.9 and 3.; mg/d) to 20 and • Central Blood Bank.
6.2 rug/d!. Thus, both of these patients had evidencE' of mild 3 Department of Pathology. delayed hemolysis at times when no bleeding was apparent.
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The third patient was a 61-year-old man who was never .
• Abbrpviations: HDN. hi>molytir dispase ofth~ npwhorn: RhIG. Rh known to have received Rh.; RBCs or platelet.." and had no unmunf globulin.
RBf' ·b d ~. anti () ies dE'tected elsewherE' (; month~ bdore transplant.
After transfusion of 10 units of Rh" RBCs, anti-D and -E were found in the serum, but not on RBCs, at 11 days, but were undetectable at another hospital two months after surgery. There were no RBC antibodies found in the plasma of his blood donors. The organ donor was Rh.., virtually ruling out the graft as the origin of the anti·D. Evaluation-for hemolysis was obscured by concurrent reoperation for biliary obstruction.
Of the other 16 patients, none had_ anti-D ~2 months later, including 13 with followup ~1l.5 months (Table 1) . Two were female patients 41 and 53 years old; the rest were male.
Two of these patients were later given Rh + RBCs again, but died shortly thereafter. Case 1 received such units a few days before death, and case 16 was given more than 50 more Rh+ units during his 2.5-month survival period.
Four other liver transplant patients with preoperative anti-D had::!: 1 month of follow-up antibody testing after surgery. In each case the anti-D was still detectable 1.5, 18, 48, and 52 months later. This suggested that immunosuppression did not interfere with the us~al long-term persistence of preexisting anti·D (7). -
DISCUSSION
In a previous retrospective blood bank study of 1000 consec· utive liver transplants in 781 patients at our center (13), many RBC antibodies appeared 1-5 weeks later, but only 3 patients were found Wilave formed new significant RBC alloantibodies (anti-K and -E) after more extended follow-up (from 7 weeks to 4.5 months). However, the true rate of primary RBC alloimmunization was uncertain because most patients did not have long-term testing. In this study of 19 Rh-organ transplant patients tested >2 months after receiving numerous Rh+ RBCs, there was only one apparently primary anti-D, there were two rapid secondary immune responses, and in 16 patients no subsequent antibody wa& found. Lack of alloimmurllzation was further suppo_rted by negative results of additional testing in 10 patients when enzyme-treated screening cells were used to enhance Rh antibody detection.
In immunocompetent subjects receiving::!:l Rh-incompatible exposure. In the 18 subjects tested monthly by Pollack et aI_ (2) , antibody first appeared in 9 at 2 months, in 7 at 3 montlu; and in 2 at 4-5 months. Furthermore, anti·D is generally ~er; persistent. We previously found that 86% of such antibodies were still present 1-60 months after detection (7). Therefol't.. anti-D would have been expected in most of Qur patients. Our lone case ofprilllary anti-D formation is similar in timing and transience to a case of anti·D after liver transplant ob. served by Blomqvist et al. (16) . After 38 units of Rh+ blood, this antibody was detected by enzyme-treated RBCs at day~ 12-16 and subsequently disappeared in a previously untrarufused male patient (Blomqvist BI, personal communication). However, the most r,apid primary anti·D response previously reported was at 4 weeks (J). It is also possible that these two patients had previously undetected levels of "naturally 0CCUl-ring" anti-D; some of these antibodies can be stimulated h) exposure (17, 1 B) .
Our findings are of praetical importance for transfusion management ofRh-organ transplant patients when Rh-blood is in short supply. Excluding our two-secondary immune responses, the frequency of subsequently detectable primary anti-D was low 0/17) after multiple Rh' RBCs. Perhaps immunosuppressive regimens could be devised for other settings oflargtRh-incompatible blood exposure. However, two cautions should be made. First, in transplant patients who may have been previously Rh-sensitized by transfusions or remote pregnancies, delayed hemolytic transfusion reactions can ensue after Rh" RBC transfusions, as -noted here and as we and othel'!' have observed with non-D RBC antibodies (IS, 19). Second. only two of our patients have been rechallenged with Rh+ RBCs, and they died shortly thereafter. In the pre-RhJG era, SOl!le women sensitized by low levels of Rh" f~tal RBCs did not produce anti-D until the next Rh+ gestation. Therefore, it i!; possible that some of our patiellts have been silent~ immunized. None were girls or women of childbearinE age (Table 1) . SincE' successful pregnancies have occurred after cyclosporine transplantation (20) , we still recommend avoidance of Rh" RBCs in -girls or young women, if feasible~ pending further data.
In the setting of cancer therapy immunosuppression, repeated Rl}-incompatible platelet and granulocyte transfusiom containing small amounts. of Rh" RBCs have led to varyin!: rates of anti-D formation. Two studies yielded 8-1BSC rates of Rh alloimmunization (21, 22) , but another group reported only a 2% frequency (23) . Our RBC datB suggest that the risk of immunization by Rh" platelets alone would be minimal in liver and heart transplantation.
Rh" RBC" in kidney grafts occasionally have ('lmsed primar), or secondary alloimmunization in Rh-transplant recipient;; odies were 500 ml of (25, 26) .
Our results in RBC transfusions may be related to experimental evidence in rats and dogs that cyclosporine can prevent transfusion-induced humoral alloimmunization to antigens of the major histocompatibility complex (27, 28) . In humans, this drug has been reported to impair T cell-dependent antibody ",sponses in bone marrow transplant recipients immunized " .. ith keyhole limpet hemocyanin (29) , and also in renal transplant patient-s who were given influenza vaccine (30) . Further ,...ork to determine whether the RBC Rh protein might also be 8 T cell-dependent antigen would be of interest. Besides cyclo· 5porine, the other immunosuppressive measures employed in our patients could have played a role in the effect we observed.
Primary antibody responses to other antigens such as vaccines or infectious-agents may also be impaired at the time of organ tra;splantation.
